2,136 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by Strategic Investment Advisors MI

Strategic Investment Advisors MI bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,136 shares of the medical research company’s stock, valued at approximately $377,000.

Several other institutional investors have also added to or reduced their stakes in the business. American National Bank & Trust purchased a new stake in shares of IQVIA in the 1st quarter worth $26,000. ST Germain D J Co. Inc. increased its position in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after buying an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the fourth quarter worth about $39,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA in the fourth quarter worth about $44,000. Finally, Zions Bancorporation N.A. lifted its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 0.1%

Shares of IQV opened at $158.77 on Thursday. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. The stock has a market capitalization of $27.47 billion, a price-to-earnings ratio of 21.63, a price-to-earnings-growth ratio of 1.73 and a beta of 1.28. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The business’s 50 day simple moving average is $148.69 and its 200-day simple moving average is $175.18.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The company had revenue of $3.83 billion for the quarter, compared to analysts’ expectations of $3.77 billion. During the same quarter in the previous year, the business posted $2.54 earnings per share. IQVIA’s quarterly revenue was up 2.5% on a year-over-year basis. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on IQV. Redburn Partners set a $188.00 target price on shares of IQVIA in a report on Friday, May 23rd. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. UBS Group lowered their target price on shares of IQVIA from $255.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a report on Monday, May 19th. Finally, Truist Financial decreased their price target on IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a report on Thursday, April 10th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.